RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

Cancer Biology and Therapy

Volumn 13, Issue 4, 2012, Pages 206-215

  Ji, Shunrong ^a,b   Xu, Jin ^b   Zhang, Bo ^a,b   Yao, Wantong ^a,b   Xu, Wenyan ^a,b   Wu, Wenzhe ^c   Xu, Yongfeng ^a,b   Wang, Hao ^c   Ni, Quanxing ^a,b   Hou, Huimin ^c   Yu, Xianjun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c National Pharmaceutical Engineering Research Center   (China)

Author keywords

Albumin; Delivery; FITC; Nanoparticles; Pancreatic cancer; RGD; Therapy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BOVINE SERUM ALBUMIN NANOPARTICLE; FLUORESCEIN ISOTHIOCYANATE; GEMCITABINE; NANOPARTICLE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL NUCLEUS; CELL TRANSPORT; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDIATOR; MOUSE; NANOENCAPSULATION; NONHUMAN; PANCREAS CANCER; PROTEIN BINDING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SPECTROFLUOROMETRY; SPECTROPHOTOMETER;

ALBUMINS; ANIMALS; CATTLE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; OLIGOPEPTIDES; PANCREATIC NEOPLASMS;

EID: 84863137334     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.4.18692     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2008; 58:71-96; PMID:18287387; http://dx.doi.org/10.3322/CA.2007.0010
2. Li D, Xie KP, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57; PMID:15051286; http://dx.doi.org/10.1016/S0140-6736(04)15841-8
3. Linder S, Bostrom L, Nilsson B. Pancreatic cancer in Sweden 1980-2000: a population-based study of hospitalized patients concerning time trends in curative surgery and other interventional therapies. J Gastrointest Surg 2006; 10:672-8; PMID:16713540; http://dx.doi. org/10.1016/j.gassur.2005.10.005
4. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17:403-9; PMID: 16596292; http://dx.doi.org/10.1007/ s10552-005-0539-4
5. Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 2005; 390: 94-103; PMID:15578211; http://dx.doi.org/10.1007/s00423-004-0476-9
6. Schäfer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 2002; 236:137-48; PMID:12170018; http://dx.doi.org/10.1097/00000658-200208000-00001
7. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5:19-33; PMID: 12127861; http://dx.doi.org/10.1016/S1368-7646(02)00002-X
8. Heister E, Neves V, Tilmaciu C, Lipert K, Beltran VS, Coley HM, et al. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. Carbon 2009; 47: 2152-60; http://dx.doi.org/10.1016/j.carbon.2009.03.057
9. Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des 2008; 14: 1124-37; PMID:18473859; http://dx.doi.org/10.2174/ 138161208784246216
10. Yang J, Park SB, Yoon HG, Huh YM, Haam S. Preparation of poly epsilon-caprolactone nanoparticles containing magnetite for magnetic drug carrier. Int J Pharm 2006; 324:185-90; PMID:16872766; http://dx.doi.org/10.1016/ j.ijpharm.2006.06.029
11. Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroti D, et al. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 2004; 4:63; PMID:15363094; http://dx.doi.org/10. 1186/1471-2407-4-63
12. Kurrat R, Prenosil JE, Ramsden JJ. Kinetics of human and bovine serum albumin adsorption at silica-titania surfaces. J Colloid Interface Sci 1997; 185:1-8; PMID: 9056288; http://dx.doi.org/10.1006/jcis.1996.4528
13. Gelamo EL, Tabak M. Spectroscopic studies on the interaction of bovine (BSA) and human (HSA) serum albumins with ionic surfactants. Spectrochim Acta A Mol Biomol Spectrosc 2000; 56A:2255-71; PMID:11058071; http://dx.doi.org/10. 1016/S1386-1425(00)00313-9
14. Zhang L, Hou SX, Mao SJ, Wei DP, Song XJ, Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm 2004; 287:155-62; PMID:15541922; http://dx.doi.org/10.1016/j.ijpharm.2004.08.015
15. Ulbrich K, Hekmataraa T, Herberta E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251-6; PMID:18805484; http://dx.doi.org/10.1016/j.ejpb.2008.08.021
16. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, et al. RGD-peptides induce apoptosis by direct caspase-3 activation. Nature 1999; 397:534-9; PMID:10028971; http://dx.doi.org/10.1038/ 17409
17. Anuradha CD, Kanno S, Hirano S. RGD peptide-induced apoptosis in human leukemia HL-60 cells requires caspase-3 activation. Cell Biol Toxicol 2000; 16:275-83; PMID:11201051; http://dx.doi.org/10.1023/A:1026758429238
18. Madeja Z, Sroka J. Contact guidance of Walker carcinosarcoma cells by the underlying normal fibroblasts is inhibited by RGD-containing synthetic peptides. Folia Histochem Cytobiol 2002; 40:251-60; PMID:12219835
19. Kang IC, Kim DS, Jang Y, Chung KH. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis. Biochem Biophys Res Commun 2000; 275:169-73; PMID:10944460; http://dx.doi.org/10.1006/bbrc.2000.3130
20. Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, et al. Abrogation of the interaction between osteopontin and αvβ3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 2007; 57:302-10;PMID:17482311; http://dx.doi.org/10.1016/j.lungcan.2007.03.019
21. Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and Function of b1 and αvβ3 Integrins in Ovarian Cancer. Gynecol Oncol 1995; 58: 216-25; PMID:7542622; http://dx.doi.org/10.1006/gyno.1995.1214
22. Borrirukwanit K, Lafleur MA, Mercuri FA, Blick T, Price JT, Fridman R, et al. The type I collagen induction of MT1-MMP-mediated MMP-2 activation is repressed by αvβ3 integrin in human breast cancer cells. Matrix Biol 2007; 26:291-305; PMID:17175151; http://dx.doi.org/10.1016/j.matbio.2006.10.014
23. Tzukert K, Shimony N, Krasny L, Urieli-Shoval S, Gorodetsky R, Avrahami I, et al. Human melanoma cells expressing the αvβ3 integrin are partially protected from necrotic cell death induced by dynamic matrix detachment. Cancer Lett 2010; 290:174-81; PMID:19804941; http://dx.doi.org/10. 1016/j.canlet.2009.09.007
24. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC, Jr., Brekken RA, et al. Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 2005; 200: 371-7; PMID:15737847; http://dx.doi.org/10.1016/j. jamcollsurg.2004.10.005
25. Hosotani R, Kawaguchi M, Masui T, Koshiba T, Ida J, Fujimoto K, et al. Expression of integrin αvβ3 in pancreatic carcinoma: relation to mmp-2 activation and lymph node metastasis. Pancreas 2002; 25:30-5; http://dx.doi.org/10.1097/00006676-200208000-00021
26. Li JM, Chen W, Wang H, Jin C, Yu XJ, Lu WY, et al. Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. Acta Pharmacol Sin 2009; 30:1337-43; PMID: 19730429; http://dx.doi.org/10.1038/aps.2009.125
27. Tomita M, Sugi H, Ozawa K, Tsong TY, Yoshimura T. Targeting antigen-specific receptors on B lymphocytes to generate high yields of specific monoclonal antibodies directed against biologically active lower antigenic peptides within presenilin 1. J Immunol Methods 2001; 251:31-43; PMID:11292479; http://dx.doi.org/ 10.1016/S0022-1759(01)00299-X
28. Du SL, Pan H, Lu WY, Wang J, Wu J, Wang JY. Cyclic RGD peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007; 322:560-8; PMID:17510318; http://dx. doi.org/10.1124/jpet.107. 122481
29. Zhang J, Chen XG, PengWB, Liu CS. Uptake of oleoylchitosan nanoparticles by A549 cells. Nanomedicine 2008; 4:208-14; PMID:18508414; http://dx.doi.org/10. 1016/j.nano.2008.03.006
30. Merkel OM, Germershaus O, Wada CK, Tarcha PJ, Merdan T, Kissel T. Integrin αvβ3 targeted gene delivery using rgd peptidomimetic conjugates with copolymers of pegylated poly (ethylene imine). Bioconjug Chem 2009; 20:1270-80; PMID:19476331; http://dx.doi.org/10.1021/bc9001695
31. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 2000; 194:91-102; PMID:10601688; http://dx.doi.org/10.1016/S0378-5173(99)00370-1
32. Son SJ, Bai X, Lee SB. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 2: Imaging, diagnostic, and therapeutic applications. Drug Discov Today 2007; 12:657-63; PMID:17706548; http://dx.doi.org/10.1016/j.drudis. 2007.06.012
33. Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS. Radiotherapy combined with gemcitabine and oxaliplatinin pancreatic cancer cells. Transl Oncol 2008; 1:36-43; PMID:18607506